Purpose: To evaluate the perception of efficacy and tolerability of ZYTER, a newly registered and marketed topical antibiotic treatment composed of azithromycin 1.5%, in Mexican patients and ophthalmologists. Azithromycin is approved by the Regulatory Agency of Mexico. Material and methods: Phase IV, open, observational, non-comparative survey in 560 Mexican patients with bacterial conjunctivitis. ZYTER was applied 2 times daily during 3 days. An evaluation of ocular signs and symptoms was performed on D0 (inclusion visit), D3 (end of the treatment) and D8. Global efficacy and tolerability were scored by the patient and his Doctor. Results: On the inclusion visit D0, ocular signs were rated as moderate to severe in 56 to 69% of the patients. At D8, no severe signs were reported. One to 4% of the residual signs were moderate and 16 to 39% were mild. At D0, each symptom was present in 85 to 93% of the patients and rated by the patients as moderate to severe in more than 60% of cases. At D8, symptoms were absent in 64 to 71% of the patients. At D0, 58 to 71% of the symptoms were marked. At D8, symptoms became mild or absent in more than 96% of the patients. Symptoms resolution was obtained as soon as D3. Signs improvement was more gradual, with a partial result at D3 and a final result at D8 showing almost full recovery. Tolerability was rated as satisfactory or very satisfactory by 95% of the patients at both D1 and D3. Conclusion: The results of this “real life study” in Mexico meets the previous ones from controlled trials. ZYTER is a safe and efficient treatment for bacterial conjunctivitis, with the valuable advantage of a shortened treatment duration and an accelerated relief.